Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Exclusion Criteria

• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No condition that potentially impairs the ability to swallow or absorb AZD0530, including any of the following:
• •* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• •* Active peptic ulcer disease
• •* Short gut syndrome
• •* Malabsorption syndrome of any type
• •* Total or partial bowel obstruction
• •* Inability to tolerate oral medications
• •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530
• •No QTc prolongation (defined as a QTc interval ≥ 460 msec) or other significant electrocardiogram (ECG) abnormalities
• •No poorly controlled hypertension (i.e., systolic blood pressure \[BP\] ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg)
• •No history of ischemic heart disease, including myocardial infarction
• •No concurrent cardiac dysfunction including, but not limited to, any of the following:
• •* Symptomatic congestive heart failure
• •* Unstable angina pectoris
• •* Cardiac arrhythmia
• •No other concurrent uncontrolled illness, including ongoing or active infection or psychiatric illness/social situations, that would limit compliance with study requirements
• •Prior chemotherapy allowed provided it was administered as part of initial curative intent therapy (i.e., neoadjuvant therapy, adjuvant therapy and/or concurrently with radiotherapy) in combination with surgery
• •* At least 4 weeks since prior chemotherapy
• •At least 4 weeks since prior and no more than 1 line of palliative chemotherapy for advanced disease
• •At least 4 weeks since prior radiotherapy and recovered
• •At least 4 weeks since prior major surgery and recovered
• •No cytochrome 450 3A4 (CYP3A4) active agents or substances for ≥ 7 days before, during, and for ≥ 7 days after completion of study treatment
• •No other concurrent investigational agents
• •No other concurrent anticancer therapy
• •No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients